Pfizer strategy chief Andrew Baum departs, stays on as senior advisor; Helus Pharma appoints new CEO after two months
read at Endpoints ↗Neutral
Andrew Baum, formerly chief strategy and innovation officer at Pfizer, has left that role.
He will continue to work with the company as a senior strategic advisor to CEO Albert Bourla.
Meanwhile, Helus Pharma announced a leadership change, replacing its chief executive after only two months in the position.
The brief tenure underscores the challenges of executive stability in biotech firms.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Pfizer’s strategy chief Andrew Baum steps down; Helus Pharma swaps out CEO after two months”
read at Endpoints ↗95 words · retrieved Apr 26
comments(0)
5-min edit window · permanent after that